Lilly cancer drug lands accelerated FDA approval
Lartruvo is the first front-line therapy approved by the FDA to treat soft tissue sarcomas since doxorubicin more than 40 years ago.
Cancer
Articles
Purdue startup focuses on prostate cancer therapy
Research developed at Purdue University and licensed by a biomedical startup could give patients with late-stage prostate cancer an alternative to hormone therapies that can develop resistance after prolonged use.
Biotech firm lands funding for cancer targeting
Animated Dynamics Inc. has raised $1.7 million in early funding to help it get its technology to market.
Bristol-Myers drug tops Lilly’s Erbitux in cancer study
Bristol-Myers Squibb Co.’s blockbuster cancer drug Opdivo prolonged survival in cases of recurrent head and neck cancer, a first for patients with the harshest form of the disease who often face a bleak prognosis.
Governor weighs in on criticism of HPV vaccine letter
The Indiana State Department of Health sent letters to 305,000 parents who haven’t vaccinated their children for a virus known to cause cervical cancer. Conservative groups have objected to what they call an intrusion into parenting decisions.
Lilly leaps into new frontier of cancer drugs
For two years, Eli Lilly and Co. has been building a team of immuno-oncology researchers in New York City and has struck a series of deals with other drug companies.
Lilly partner Immunocore raises record $320 million
Immunocore Ltd., which this week achieved the biggest private fundraising by a European biotechnology firm in 10 years, plans to accelerate development of its cancer therapy using the money and seek expedited approval.
Clot risk in Lilly lung-cancer drug raises FDA concerns
The drug, known as necitumumab, improved patients’ overall chances of survival, yet people taking the medicine also experienced more risk, Food and Drug Administration staff said in a report Tuesday.
Lilly drug regimen costing $9,200 a month scores zero in study
In a new scoring system for oncology drugs, a leading group of U.S. cancer doctors awarded a zero for overall benefit to a regimen featuring Alimta, Eli Lilly and Co.’s top-selling product.
7-year-old Simon Cancer Center already outmoded
The Indiana University Simon Cancer Center appears ill-suited for the future of cancer care and its own future is in question.
Lilly pledges $60M to German firm to form research partnership
In a bid to get into the white-hot market for drugs that use the body’s immune system, Eli Lilly and Co. will spend $60 million to form a research partnership with Germany-based BioNTech.
Diabetes drug metformin show promise in cancer
Researchers at Purdue University, the Indiana University School of Medicine and the University of Wisconsin discovered a combination of two currently available drugs significantly slowed the growth of late-stage prostate cancer tumors in mice.
Recent wins worth $4B to Lilly market value
Lilly is finally putting meat on the bones of its predictions about its experimental diabetes and cancer drugs. That gives investors the certainty they crave that Lilly’s future revenue won’t remain in its 2014 doldrums.
Lilly cancer drug fares well in late-stage study
Eli Lilly and Co. said Friday its potential colorectal cancer drug Cyramza helped patients on chemotherapy with advanced cases of the disease survive longer than patients on chemotherapy alone.
Costly drugs force cancer docs to weigh price with therapy
With new cancer drugs priced as high as $10,000 a month, and insurers tightening payment rules, patients who thought they were well covered increasingly find themselves having to make life-altering decisions about what they can afford.
Endocyte shares plunge 60 percent after drug trial is stopped
Endocyte Inc.’s stock fell more than 60 percent in early trading Friday after the drug it’s developing with Merck & Co.’s backing failed to help patients in a trial for ovarian cancer.
Cancer treatment makes Endocyte premium takeover target
Now that Indiana-based Endocyte Inc.’s experimental cancer treatment is proving successful, the company may command a takeover bid at one of the industry’s highest premiums on record.
Endocyte stock doubles after key approval in Europe
The stock price of Endocyte Inc. skyrocketed by as much as 130 percent Friday morning after the drug company got a thumbs up in Europe to market its first drug and received a new round of favorable clinical trial results.
Indiana one of many states aiming to limit tanning
Lawmakers' efforts to crack down on the use of Indiana tanning beds this year are part of a national push to limit young people's exposure to risks that include skin cancer.
Three groups puzzled by woman’s $7 million bequest
The organizations which include Indianapolis-based Hoosier Oncology Group have no idea why an Evansville teacher chose them as beneficiaries.